Data from Optimer Pharmaceuticals, Inc.'s Prulifloxacin Phase 3 Trial in Traveler’s Diarrhea and Strain Typing Data from OPT-80 Study to be Presented at ICAAC/IDSA Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Results from three studies related to Optimer Pharmaceuticals, Inc.’s (NASDAQ:OPTR) developmental product candidates will be presented at this year’s joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Disease Society of America (IDSA), to be held at the Walter E. Washington Convention Center in Washington, D.C. on October 25-28, 2008.